Grant Pickering has been the CEO of Vaxcyte, Inc. since May 2020. His leadership is anchored in the biopharmaceutical field, focusing on developing new vaccines and therapies. Under his guidance, the company has achieved significant milestones, particularly with the VAX-24...

Grant Pickering has been the CEO of Vaxcyte, Inc. since May 2020. His leadership is anchored in the biopharmaceutical field, focusing on developing new vaccines and therapies. Under his guidance, the company has achieved significant milestones, particularly with the VAX-24 vaccine, which recently showed promising results in clinical trials. Pickering's vision for Vaxcyte is clear: aim for excellence in vaccine development while aligning business goals with shareholder interests. In 2023, he earned a total compensation of over $1.17 million, which included a performance-based bonus that highlighted his ability to meet corporate goals. His decisions are directly influencing patient health through innovative biopharmaceuticals, and his role is pivotal as Vaxcyte continues to grow in a competitive industry. Interestingly, he also made significant insider trades during his tenure, peaking at a stock value of over $30 million in late 2020 and early 2021. This shows his strong belief in the company's direction and future success.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Vaxcyte, Inc. CEOs

V

Grant Pickering

CEO of Vaxcyte, Inc.

Sector of Economy

Healthcare

CEO of Vaxcyte, Inc. for

4 years 11 months (May 2020 - Present)

Previous Experience

Prior to joining Vaxcyte, Grant Pickering served as the Chief Executive Officer of another biopharmaceutical company and has extensive experience in the industry.

Rivals

Competitors/colleagues of Grant Pickering

Holdings

See how much did Grant Pickering make over time.

Grant Pickering's personal stake in Vaxcyte is notable, with his holdings fluctuating between $16.91 million and $68.52 million over the past few years. His most significant wealth was seen in the latter part of 2020, peaking as high as $30...

Grant Pickering's personal stake in Vaxcyte is notable, with his holdings fluctuating between $16.91 million and $68.52 million over the past few years. His most significant wealth was seen in the latter part of 2020, peaking as high as $30 million around June 2023 and then maintaining a robust presence in subsequent months. This pattern of holdings reflects his commitment to Vaxcyte's growth as he navigates a dynamic market landscape. These insider trading moves signal confidence in the company's trajectory and are particularly interesting given the fluctuations in overall stock value during these periods.

Total Stock Sold

$36.32M

PCVX

$36.32M

676,230 PCVX shares

What if they kept their stock?

If Grant Pickering didn't sell their stock, today they would have:
Extra PCVX676,230 shares worth $17.68M.
This is -51.31% and $18.63M less than what they got when they sold the stock.

Charitable Transactions

PCVX

710 shares

PCVX

Recent Charitable Transactions

PCVX

710 shares

PCVX

Nov 18, 2024

Charity

Insider Trading

See recent insider trades of Grant Pickering.

PCVX

$219.32K

PCVX at $92.70/share

Dec 9, 2024

Sale

PCVX

$1.40M

PCVX at $93.06/share

Dec 2, 2024

Sale

PCVX

710 shares

PCVX

Nov 18, 2024

Charity

PCVX

$246.22K

PCVX at $104.07/share

Nov 7, 2024

Sale

PCVX

$1.61M

PCVX at $107.40/share

Nov 1, 2024

Sale

PCVX

$773.50K

PCVX at $108.97/share

Oct 7, 2024

Sale

PCVX

$6.28M

PCVX at $114.20/share

Oct 1, 2024

Sale

PCVX

$1.18M

PCVX at $78.95/share

Aug 23, 2024

Sale

PCVX

$206.12K

PCVX at $78.79/share

Aug 1, 2024

Sale

PCVX

$1.26M

PCVX at $84.18/share

Jul 23, 2024

Sale

Compensation History

See how much did Grant Pickering make over time.

In 2023, Grant Pickering's total compensation reached approximately $1.17 million. This included a base salary of $640,000 and performance-based bonuses that recognized his leadership achievements in meeting corporate goals. He also received stock options granted to align his interests with those of shareholders. Notably, his bonuses reflected significant growth in the company, earning 125% of his target due to Vaxcyte's advancements, particularly around vaccine development metrics. In previous years, his compensation has steadily increased alongside the company's progress in clinical trials, reinforcing a strong pay-for-performance philosophy that drives executive motivation. This structure is designed to foster a culture of accountability and innovation within the biopharmaceutical sector.

Year

2023

Total Compensation

$1.13M

Salary

$640.00K

Board Justification

The compensation philosophy emphasizes a pay-for-performance approach, aligning executive compensation with company performance and shareholder interests, while considering market competitiveness and retention strategies.

Bonus

$480.00K

Board Justification

The annual performance-based bonus earned for 2023 was based on achieving corporate performance goals, with a payout of 125% of the target bonus due to significant progress made on objectives.

Other

$14.48K

Board Justification

Other compensation includes life insurance premiums and 401(k) matching contributions.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards vested in 2023 as the focus is on cash compensation and performance-based bonuses.

Performance Metrics

The performance metrics for 2023 included achieving corporate goals related to clinical trials and financial objectives.

Other Vaxcyte, Inc. CEOs

Here are other CEOs of Vaxcyte, Inc.

Moncef Slaoui

Ex-CEO of Vaxcyte, Inc.

July 2017 - March 2021

Andrew Guggenhime

CEO of Vaxcyte, Inc.

January 2021 - Present